AMGN—

$0.00

BIIB—

$0.00

GILD—

$0.00

REGN—

$0.00

VRTX—

$0.00

MRNA—

$0.00

BNTX—

$0.00

ILMN—

$0.00

SNY—

$0.00

VTRS—

$0.00

ALNY—

$0.00

ARGX—

$0.00

BMRN—

$0.00

ACAD—

$0.00

ALKS—

$0.00

EXEL—

$0.00

HALO—

$0.00

INCY—

$0.00

INSM—

$0.00

IONS—

$0.00

JAZZ—

$0.00

NBIX—

$0.00

NVAX—

$0.00

NVCR—

$0.00

PTCT—

$0.00

RARE—

$0.00

RPRX—

$0.00

SRPT—

$0.00

UTHR—

$0.00

PACB—

$0.00

BBIO—

$0.00

ARVN—

$0.00

BEAM—

$0.00

CRSP—

$0.00

EDIT—

$0.00

NTLA—

$0.00

RXRX—

$0.00

SMMT—

$0.00

MDGL—

$0.00

AXSM—

$0.00

AUPH—

$0.00

ADPT—

$0.00

AGIO—

$0.00

ALLO—

$0.00

ARCT—

$0.00

ARWR—

$0.00

BCRX—

$0.00

CYTK—

$0.00

DNLI—

$0.00

ENTA—

$0.00

ERAS—

$0.00

FTRE—

$0.00

GMAB—

$0.00

GERN—

$0.00

GRFS—

$0.00

GH—

$0.00

IDYA—

$0.00

IMCR—

$0.00

IMVT—

$0.00

IOVA—

$0.00

JANX—

$0.00

KYMR—

$0.00

KRYS—

$0.00

KNSA—

$0.00

LENZ—

$0.00

LGND—

$0.00

LYEL—

$0.00

MEDP—

$0.00

MIRM—

$0.00

NGNE—

$0.00

ORIC—

$0.00

PCRX—

$0.00

PRAX—

$0.00

PTGX—

$0.00

RVMD—

$0.00

RYTM—

$0.00

RCKT—

$0.00

ROIV—

$0.00

SANA—

$0.00

SRRK—

$0.00

SIGA—

$0.00

STOK—

$0.00

GPCR—

$0.00

SUPN—

$0.00

TARS—

$0.00

TSHA—

$0.00

TVTX—

$0.00

TYRA—

$0.00

QURE—

$0.00

VERA—

$0.00

VCEL—

$0.00

VIR—

$0.00

WVE—

$0.00

XNCR—

$0.00

XENE—

$0.00

ZLAB—

$0.00

ZYME—

$0.00

KROS—

$0.00

REPL—

$0.00

RGNX—

$0.00

SPRY—

$0.00

ADMA—

$0.00

AMLX—

$0.00

AMPH—

$0.00

ASND—

$0.00

SEPN—

$0.00

TBPH—

$0.00

TRVI—

$0.00

HRMY—

$0.00

PCVX—

$0.00

MNKD—

$0.00

AMGN—

$0.00

BIIB—

$0.00

GILD—

$0.00

REGN—

$0.00

VRTX—

$0.00

MRNA—

$0.00

BNTX—

$0.00

ILMN—

$0.00

SNY—

$0.00

VTRS—

$0.00

ALNY—

$0.00

ARGX—

$0.00

BMRN—

$0.00

ACAD—

$0.00

ALKS—

$0.00

EXEL—

$0.00

HALO—

$0.00

INCY—

$0.00

INSM—

$0.00

IONS—

$0.00

JAZZ—

$0.00

NBIX—

$0.00

NVAX—

$0.00

NVCR—

$0.00

PTCT—

$0.00

RARE—

$0.00

RPRX—

$0.00

SRPT—

$0.00

UTHR—

$0.00

PACB—

$0.00

BBIO—

$0.00

ARVN—

$0.00

BEAM—

$0.00

CRSP—

$0.00

EDIT—

$0.00

NTLA—

$0.00

RXRX—

$0.00

SMMT—

$0.00

MDGL—

$0.00

AXSM—

$0.00

AUPH—

$0.00

ADPT—

$0.00

AGIO—

$0.00

ALLO—

$0.00

ARCT—

$0.00

ARWR—

$0.00

BCRX—

$0.00

CYTK—

$0.00

DNLI—

$0.00

ENTA—

$0.00

ERAS—

$0.00

FTRE—

$0.00

GMAB—

$0.00

GERN—

$0.00

GRFS—

$0.00

GH—

$0.00

IDYA—

$0.00

IMCR—

$0.00

IMVT—

$0.00

IOVA—

$0.00

JANX—

$0.00

KYMR—

$0.00

KRYS—

$0.00

KNSA—

$0.00

LENZ—

$0.00

LGND—

$0.00

LYEL—

$0.00

MEDP—

$0.00

MIRM—

$0.00

NGNE—

$0.00

ORIC—

$0.00

PCRX—

$0.00

PRAX—

$0.00

PTGX—

$0.00

RVMD—

$0.00

RYTM—

$0.00

RCKT—

$0.00

ROIV—

$0.00

SANA—

$0.00

SRRK—

$0.00

SIGA—

$0.00

STOK—

$0.00

GPCR—

$0.00

SUPN—

$0.00

TARS—

$0.00

TSHA—

$0.00

TVTX—

$0.00

TYRA—

$0.00

QURE—

$0.00

VERA—

$0.00

VCEL—

$0.00

VIR—

$0.00

WVE—

$0.00

XNCR—

$0.00

XENE—

$0.00

ZLAB—

$0.00

ZYME—

$0.00

KROS—

$0.00

REPL—

$0.00

RGNX—

$0.00

SPRY—

$0.00

ADMA—

$0.00

AMLX—

$0.00

AMPH—

$0.00

ASND—

$0.00

SEPN—

$0.00

TBPH—

$0.00

TRVI—

$0.00

HRMY—

$0.00

PCVX—

$0.00

MNKD—

$0.00

Equities

Approvals, trial readouts, earnings and deals at listed biotech and pharmaceutical companies.

All Commentary Equities Policy Geopolitics

Sartorius (SRT3; SRT) reports improving margins as equipment demand recovers

Sartorius (SRT3; SRT) reports improving margins as equipment demand recovers

Editorial Team22 October 2026 · 3 min

Pharming Group (PHAR; PHARM) reports stronger quarter and narrows annual guidance

Pharming Group (PHAR; PHARM) reports stronger quarter and narrows annual guidance

Editorial Team22 October 2026 · 3 min

Ipsen (IPN) raises sales and margin expectations after strong third quarter

Ipsen (IPN) raises sales and margin expectations after strong third quarter

Editorial Team22 October 2026 · 3 min

Rezera (proposed Nasdaq: RZRA) prepares IPO for cardiovascular inflammation programme

Rezera (proposed Nasdaq: RZRA) prepares IPO for cardiovascular inflammation programme

Editorial Team22 October 2026 · 3 min

Roche (ROG) drops a Poseida CAR-T candidate while defending the acquisition

Roche (ROG) drops a Poseida CAR-T candidate while defending the acquisition

Editorial Team22 October 2026 · 3 min

QIAGEN (QGEN) agrees €46.50-a-share takeover framework with EQT

QIAGEN (QGEN) agrees €46.50-a-share takeover framework with EQT

Editorial Team22 October 2026 · 3 min

Roche (ROG) adds lesion and brain-volume data to fenebrutinib's MS case

Roche (ROG) adds lesion and brain-volume data to fenebrutinib's MS case

Editorial Team21 October 2026 · 3 min

CSL (ASX: CSL) recruits GSK's Deborah Waterhouse to lead its recovery

CSL (ASX: CSL) recruits GSK's Deborah Waterhouse to lead its recovery

Editorial Team21 October 2026 · 3 min

Astellas Pharma (TSE: 4503) signs miniprotein discovery deal with AI Proteins

Astellas Pharma (TSE: 4503) signs miniprotein discovery deal with AI Proteins

Editorial Team21 October 2026 · 3 min

Alcon (ALC) commits $550m to Neurotech and retinal cell therapy

Alcon (ALC) commits $550m to Neurotech and retinal cell therapy

Editorial Team21 October 2026 · 3 min

BioCryst Pharmaceuticals (BCRX) expands Orladeyo pellet access to older patients

BioCryst Pharmaceuticals (BCRX) expands Orladeyo pellet access to older patients

Editorial Team21 October 2026 · 3 min

Roivant Sciences (ROIV) posts two Phase 3 wins for brepocitinib in uveitis

Roivant Sciences (ROIV) posts two Phase 3 wins for brepocitinib in uveitis

Editorial Team21 October 2026 · 3 min

Arcus Biosciences (RCUS) broadens casdatifan's kidney-cancer ambitions

Arcus Biosciences (RCUS) broadens casdatifan's kidney-cancer ambitions

Editorial Team20 October 2026 · 3 min

Odyssey Therapeutics (ODTX) completes OD-001 induction analysis in ulcerative colitis

Odyssey Therapeutics (ODTX) completes OD-001 induction analysis in ulcerative colitis

Editorial Team20 October 2026 · 3 min

Amgen (AMGN) and AstraZeneca (AZN) strengthen Tezspire's oesophagitis case

Amgen (AMGN) and AstraZeneca (AZN) strengthen Tezspire's oesophagitis case

Editorial Team20 October 2026 · 3 min

GSK (GSK) wins US approval for Hibsago in chronic hepatitis B

GSK (GSK) wins US approval for Hibsago in chronic hepatitis B

Editorial Team20 October 2026 · 3 min

MaaT Pharma (MAAT) advances US development talks as funding remains critical

MaaT Pharma (MAAT) advances US development talks as funding remains critical

Editorial Team19 October 2026 · 3 min

Clene (CLNN) submits CNM-Au8 application for accelerated ALS approval

Clene (CLNN) submits CNM-Au8 application for accelerated ALS approval

Editorial Team19 October 2026 · 3 min

CorMedix (CRMD) secures priority review for Rezzayo prevention indication

CorMedix (CRMD) secures priority review for Rezzayo prevention indication

Editorial Team19 October 2026 · 3 min

SpyGlass Pharma (SGP) adds four-year evidence for its glaucoma implant

SpyGlass Pharma (SGP) adds four-year evidence for its glaucoma implant

Editorial Team19 October 2026 · 3 min

GSK (GSK) wins Jemperli approval in biomarker-defined rectal cancer

GSK (GSK) wins Jemperli approval in biomarker-defined rectal cancer

Editorial Team19 October 2026 · 3 min

Organon (OGN) reports six-year Miudella data supporting a longer-use label

Organon (OGN) reports six-year Miudella data supporting a longer-use label

Editorial Team16 October 2026 · 3 min

Johnson & Johnson (JNJ) wins CHMP backing for earlier Talvey combination use

Johnson & Johnson (JNJ) wins CHMP backing for earlier Talvey combination use

Editorial Team16 October 2026 · 3 min

Ionis Pharmaceuticals (IONS) moves closer to broader European Tryngolza use

Ionis Pharmaceuticals (IONS) moves closer to broader European Tryngolza use

Editorial Team16 October 2026 · 3 min

Viatris (VTRS) and Opus Genetics (IRD) gain presbyopia approval for Ryzumvi

Viatris (VTRS) and Opus Genetics (IRD) gain presbyopia approval for Ryzumvi

Editorial Team16 October 2026 · 3 min

Asahi Kasei (TSE: 3407) Gains FDA Approval for Oral Antiviral Hovilpri

Asahi Kasei (TSE: 3407) Gains FDA Approval for Oral Antiviral Hovilpri

Editorial Team12 October 2026 · 3 min

IRulya Therapeutics (NASDAQ: IRLA), Formerly Quince, Begins New Chapter in Lung Disease

IRulya Therapeutics (NASDAQ: IRLA), Formerly Quince, Begins New Chapter in Lung Disease

Editorial Team12 October 2026 · 3 min

Akeso (HKEX: 9926) Starts Phase 3 Perioperative Colon Cancer Study of Cadonilimab

Akeso (HKEX: 9926) Starts Phase 3 Perioperative Colon Cancer Study of Cadonilimab

Editorial Team10 October 2026 · 3 min

Vaxcyte (NASDAQ: PCVX) Closes $1.15 Billion Financing for Vaccine Development and Scale-Up

Vaxcyte (NASDAQ: PCVX) Closes $1.15 Billion Financing for Vaccine Development and Scale-Up

Editorial Team10 October 2026 · 3 min

Roche (SIX: ROP) Gains Tecentriq Approval in Biomarker-Defined Colon Cancer

Roche (SIX: ROP) Gains Tecentriq Approval in Biomarker-Defined Colon Cancer

Editorial Team9 October 2026 · 3 min

Teva (NYSE: TEVA) Wins FDA Approval for Monthly Schizophrenia Injection Weltruza

Teva (NYSE: TEVA) Wins FDA Approval for Monthly Schizophrenia Injection Weltruza

Editorial Team9 October 2026 · 3 min

Retension Pharmaceuticals (NASDAQ: RTSN) Prices $45 Million IPO to Advance Hypertension Drug

Retension Pharmaceuticals (NASDAQ: RTSN) Prices $45 Million IPO to Advance Hypertension Drug

Editorial Team9 October 2026 · 3 min

TRexBio (NASDAQ: TRXB) Prices $116.7 Million IPO for Immunology Development

TRexBio (NASDAQ: TRXB) Prices $116.7 Million IPO for Immunology Development

Editorial Team9 October 2026 · 3 min

Newron Pharmaceuticals (SIX: NWRN) Details Safety Questions Behind Continuing US Evenamide Hold

Newron Pharmaceuticals (SIX: NWRN) Details Safety Questions Behind Continuing US Evenamide Hold

Editorial Team8 October 2026 · 3 min

Edgewise Therapeutics (NASDAQ: EWTX) Starts Phase 2 Dosing in Preserved-Ejection-Fraction Heart Failure

Edgewise Therapeutics (NASDAQ: EWTX) Starts Phase 2 Dosing in Preserved-Ejection-Fraction Heart Failure

Editorial Team8 October 2026 · 3 min

Glaukos (NYSE: GKOS) Licenses RevOpsis Retinal Biologic and Discovery Platform

Glaukos (NYSE: GKOS) Licenses RevOpsis Retinal Biologic and Discovery Platform

Editorial Team8 October 2026 · 3 min

Bristol Myers Squibb (NYSE: BMY) Reports Progression-Free Survival Benefit for Zenbexus Regimen

Bristol Myers Squibb (NYSE: BMY) Reports Progression-Free Survival Benefit for Zenbexus Regimen

Editorial Team8 October 2026 · 3 min

Argenx (NASDAQ: ARGX) Takes FB102 Towards Phase 3 After Coeliac Disease Win

Argenx (NASDAQ: ARGX) Takes FB102 Towards Phase 3 After Coeliac Disease Win

Editorial Team8 October 2026 · 3 min

Argenx (NASDAQ: ARGX) Stops Vyvgart Sjögren’s Study for Futility

Argenx (NASDAQ: ARGX) Stops Vyvgart Sjögren’s Study for Futility

Editorial Team8 October 2026 · 3 min

Viatris (NASDAQ: VTRS) Agrees $1.65 Billion Purchase of Pacira BioSciences (NASDAQ: PCRX)

Viatris (NASDAQ: VTRS) Agrees $1.65 Billion Purchase of Pacira BioSciences (NASDAQ: PCRX)

Editorial Team8 October 2026 · 3 min

Zealand Pharma (NASDAQ COPENHAGEN: ZEAL) and Roche (SIX: ROG) Add Diabetes Data for Petrelintide

Zealand Pharma (NASDAQ COPENHAGEN: ZEAL) and Roche (SIX: ROG) Add Diabetes Data for Petrelintide

Editorial Team7 October 2026 · 3 min

Cadrenal Therapeutics (NASDAQ: CVKD) Broadens Strategic Review Across Cardiology Pipeline

Cadrenal Therapeutics (NASDAQ: CVKD) Broadens Strategic Review Across Cardiology Pipeline

Editorial Team7 October 2026 · 3 min

Ultragenyx (NASDAQ: RARE) Agrees $210 Million Priority Review Voucher Sale

Ultragenyx (NASDAQ: RARE) Agrees $210 Million Priority Review Voucher Sale

Editorial Team7 October 2026 · 3 min

Caribou Biosciences (NASDAQ: CRBU) Halts CAR-T Development and Seeks Strategic Alternatives

Caribou Biosciences (NASDAQ: CRBU) Halts CAR-T Development and Seeks Strategic Alternatives

Editorial Team6 October 2026 · 3 min

Spyre Therapeutics (NASDAQ: SYRE) Prices $350 Million Offering to Fund Immunology Expansion

Spyre Therapeutics (NASDAQ: SYRE) Prices $350 Million Offering to Fund Immunology Expansion

Editorial Team6 October 2026 · 3 min

AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) Report Frontline Lymphoma Win for Epcoritamab

AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) Report Frontline Lymphoma Win for Epcoritamab

Editorial Team5 October 2026 · 3 min

Standard BioTools (NASDAQ: LAB) Agrees Microfluidics Sale to ARCHIMED

Standard BioTools (NASDAQ: LAB) Agrees Microfluidics Sale to ARCHIMED

Editorial Team5 October 2026 · 3 min

Korro Bio (NASDAQ: KRRO) Begins Human Dosing of RNA-Editing Candidate KRRO-121

Korro Bio (NASDAQ: KRRO) Begins Human Dosing of RNA-Editing Candidate KRRO-121

Editorial Team5 October 2026 · 3 min

Shionogi (TSE: 4507) Agrees $2 Billion IntraBio Acquisition to Expand Rare Disease Business

Shionogi (TSE: 4507) Agrees $2 Billion IntraBio Acquisition to Expand Rare Disease Business

Editorial Team5 October 2026 · 3 min

Genmab (NASDAQ: GMAB) Strengthens Rina-S Case With Ovarian Cancer Response Data

Genmab (NASDAQ: GMAB) Strengthens Rina-S Case With Ovarian Cancer Response Data

Editorial Team5 October 2026 · 3 min

Eli Lilly (NYSE: LLY) Expands Gate Bioscience Alliance With Up to $870 Million in Potential Payments

Eli Lilly (NYSE: LLY) Expands Gate Bioscience Alliance With Up to $870 Million in Potential Payments

Editorial Team5 October 2026 · 3 min

Vaxcyte (NASDAQ: PCVX) Clears Phase 3 Vaccine Endpoints, With Comparator Details That Matter

Vaxcyte (NASDAQ: PCVX) Clears Phase 3 Vaccine Endpoints, With Comparator Details That Matter

Editorial Team5 October 2026 · 3 min

Alector (NASDAQ: ALEC) Licenses Parkinson's Programme to Roche (SIX: ROG) for $100 Million Upfront

Alector (NASDAQ: ALEC) Licenses Parkinson's Programme to Roche (SIX: ROG) for $100 Million Upfront

Editorial Team5 October 2026 · 3 min

CSL (ASX: CSL) Commits $355 Million to Alentis' Kidney and Liver Programme

CSL (ASX: CSL) Commits $355 Million to Alentis' Kidney and Liver Programme

Editorial Team4 October 2026 · 3 min

Pfizer (NYSE: PFE) Builds Tilrekimig's Case for Monthly Eczema Treatment

Pfizer (NYSE: PFE) Builds Tilrekimig's Case for Monthly Eczema Treatment

Editorial Team4 October 2026 · 3 min

GeneDx (Nasdaq: WGS) Simplifies Genomic Test Ordering for Paediatricians

GeneDx (Nasdaq: WGS) Simplifies Genomic Test Ordering for Paediatricians

Editorial Team4 October 2026 · 3 min

Verastem Oncology (Nasdaq: VSTM) Explores Broader Molecular Subgroups in Ovarian Cancer

Verastem Oncology (Nasdaq: VSTM) Explores Broader Molecular Subgroups in Ovarian Cancer

Editorial Team3 October 2026 · 3 min

Agenus (Nasdaq: AGEN) Reports Three-Year Ovarian Cancer Survival Estimate

Agenus (Nasdaq: AGEN) Reports Three-Year Ovarian Cancer Survival Estimate

Editorial Team3 October 2026 · 3 min

BioMarin (Nasdaq: BMRN) Reports Long-Term Pompe Disease Follow-Up

BioMarin (Nasdaq: BMRN) Reports Long-Term Pompe Disease Follow-Up

Editorial Team3 October 2026 · 3 min

Biogen (Nasdaq: BIIB) Extends Litifilimab's Cutaneous Lupus Dataset to One Year

Biogen (Nasdaq: BIIB) Extends Litifilimab's Cutaneous Lupus Dataset to One Year

Editorial Team3 October 2026 · 3 min

Pfizer (NYSE: PFE) Details Litfulo's Phase III Vitiligo Results

Pfizer (NYSE: PFE) Details Litfulo's Phase III Vitiligo Results

Editorial Team2 October 2026 · 3 min

Mineralys Therapeutics (Nasdaq: MLYS) Prepares Lorundrostat Sleep-Apnoea Presentation

Mineralys Therapeutics (Nasdaq: MLYS) Prepares Lorundrostat Sleep-Apnoea Presentation

Editorial Team2 October 2026 · 3 min

Arvinas (Nasdaq: ARVN) Sets Up a Parkinson's Biomarker Disclosure

Arvinas (Nasdaq: ARVN) Sets Up a Parkinson's Biomarker Disclosure

Editorial Team2 October 2026 · 3 min

Replimune (Nasdaq: REPL) Launches Tudriqev in the United States

Replimune (Nasdaq: REPL) Launches Tudriqev in the United States

Editorial Team1 October 2026 · 3 min

Sagimet Biosciences (Nasdaq: SGMT) Closes $115 Million Financing

Sagimet Biosciences (Nasdaq: SGMT) Closes $115 Million Financing

Editorial Team1 October 2026 · 3 min

Regeneron (Nasdaq: REGN) Builds a Muscle-Preservation Case for Trevogrumab

Regeneron (Nasdaq: REGN) Builds a Muscle-Preservation Case for Trevogrumab

Editorial Team1 October 2026 · 3 min

Otsuka Holdings (TSE: 4578) Moves Taiho's Oral Azacitidine Combination Towards Filing

Otsuka Holdings (TSE: 4578) Moves Taiho's Oral Azacitidine Combination Towards Filing

Editorial Team1 October 2026 · 3 min

Eli Lilly (NYSE: LLY) Adds Cardiovascular Detail to Foundayo's Diabetes Case

Eli Lilly (NYSE: LLY) Adds Cardiovascular Detail to Foundayo's Diabetes Case

Editorial Team1 October 2026 · 3 min

Bristol Myers Squibb (NYSE: BMY) Faces Safety Questions Ahead of Admilparant Readout

Bristol Myers Squibb (NYSE: BMY) Faces Safety Questions Ahead of Admilparant Readout

Editorial Team1 October 2026 · 3 min

Foghorn Therapeutics (Nasdaq: FHTX) Cuts 40% of Staff as Eli Lilly (NYSE: LLY) Partnership Ends

Foghorn Therapeutics (Nasdaq: FHTX) Cuts 40% of Staff as Eli Lilly (NYSE: LLY) Partnership Ends

Editorial Team1 October 2026 · 3 min

Sanofi (Nasdaq: SNY) Commits $1 Billion to Expanded Regeneron (Nasdaq: REGN) Alliance

Sanofi (Nasdaq: SNY) Commits $1 Billion to Expanded Regeneron (Nasdaq: REGN) Alliance

Editorial Team1 October 2026 · 3 min

Gerresheimer (Xetra: GXI) Completes Centor Sale to Reduce Debt

Gerresheimer (Xetra: GXI) Completes Centor Sale to Reduce Debt

Editorial Team1 October 2026 · 3 min

Zealand Pharma (Nasdaq Copenhagen: ZEAL) Reports Survodutide Phase III Results

Zealand Pharma (Nasdaq Copenhagen: ZEAL) Reports Survodutide Phase III Results

Editorial Team1 October 2026 · 3 min

AnaCardio (Private) Raises €62.5 Million for Heart-Failure Development

AnaCardio (Private) Raises €62.5 Million for Heart-Failure Development

Editorial Team1 October 2026 · 3 min

Teva (NYSE: TEVA) Names Serge Rogasik to Lead TAPI

Teva (NYSE: TEVA) Names Serge Rogasik to Lead TAPI

Editorial Team1 October 2026 · 3 min

AbbVie (NYSE: ABBV) Explores Longer Dosing Intervals for Its Amylin Candidate

AbbVie (NYSE: ABBV) Explores Longer Dosing Intervals for Its Amylin Candidate

Editorial Team30 September 2026 · 3 min

Vanda Pharmaceuticals (Nasdaq: VNDA) Pursues Another Hetlioz Sleep Indication

Vanda Pharmaceuticals (Nasdaq: VNDA) Pursues Another Hetlioz Sleep Indication

Editorial Team30 September 2026 · 3 min

Novo Nordisk (NYSE: NVO) Reshapes US Sales Organisation With 108 Job Cuts

Novo Nordisk (NYSE: NVO) Reshapes US Sales Organisation With 108 Job Cuts

Editorial Team30 September 2026 · 3 min

BioMarin (Nasdaq: BMRN) Cuts 117 Roles as Novato Footprint Shrinks

BioMarin (Nasdaq: BMRN) Cuts 117 Roles as Novato Footprint Shrinks

Editorial Team30 September 2026 · 3 min

GSK (LSE: GSK) Selects Wave Life Sciences (Nasdaq: WVE) Liver Programme

GSK (LSE: GSK) Selects Wave Life Sciences (Nasdaq: WVE) Liver Programme

Editorial Team30 September 2026 · 3 min

Merck (NYSE: MRK) Builds Tulisokibart's Case Beyond Bowel Disease

Merck (NYSE: MRK) Builds Tulisokibart's Case Beyond Bowel Disease

Editorial Team30 September 2026 · 3 min

Eli Lilly (NYSE: LLY) Advances Amylin Combination After Strong Weight-Loss Result

Eli Lilly (NYSE: LLY) Advances Amylin Combination After Strong Weight-Loss Result

Editorial Team30 September 2026 · 3 min

Amgen Adds Detail to Daxdilimab's Discoid Lupus Result

Amgen Adds Detail to Daxdilimab's Discoid Lupus Result

Editorial Team30 September 2026 · 3 min

Petrelintide's Dose Detail Shifts Attention to Tolerability

Petrelintide's Dose Detail Shifts Attention to Tolerability

Editorial Team30 September 2026 · 3 min

Retatrutide's Fuller Dataset Sharpens Lilly's Next Launch Case

Retatrutide's Fuller Dataset Sharpens Lilly's Next Launch Case

Editorial Team30 September 2026 · 3 min

Iovance Raises Revenue Expectations as Demand Builds

Iovance Raises Revenue Expectations as Demand Builds

Editorial Team29 September 2026 · 3 min

Enanta Trims Its Workforce Ahead of Pipeline Decisions

Enanta Trims Its Workforce Ahead of Pipeline Decisions

Editorial Team29 September 2026 · 3 min

Ai3Bio Raises $48 Million to Target Disease-Driving T Cells

Ai3Bio Raises $48 Million to Target Disease-Driving T Cells

Editorial Team29 September 2026 · 3 min

UniQure's Four-Year Data Complicate the Huntington's Case

UniQure's Four-Year Data Complicate the Huntington's Case

Editorial Team29 September 2026 · 3 min

AstraZeneca Buys Into Summit's Combination Strategy

AstraZeneca Buys Into Summit's Combination Strategy

Editorial Team29 September 2026 · 3 min

AbbVie Prepares Juvmo's Parkinson's Launch

AbbVie Prepares Juvmo's Parkinson's Launch

Editorial Team28 September 2026 · 3 min

Mirum's Hepatitis Delta Study Delivers a Pivotal Win

Mirum's Hepatitis Delta Study Delivers a Pivotal Win

Editorial Team28 September 2026 · 3 min

Gazyva's Kidney Approval Broadens Roche's Autoimmune Business

Gazyva's Kidney Approval Broadens Roche's Autoimmune Business

Editorial Team28 September 2026 · 3 min

Kodiak's Eye Trial Puts Treatment Durability Back in Focus

Kodiak's Eye Trial Puts Treatment Durability Back in Focus

Editorial Team28 September 2026 · 3 min

City Therapeutics Joins the Biotech IPO Queue

City Therapeutics Joins the Biotech IPO Queue

Editorial Team26 September 2026 · 3 min

Novotech Agrees to Buy Australian Bioanalytical Specialist

Novotech Agrees to Buy Australian Bioanalytical Specialist

Editorial Team25 September 2026 · 3 min

Lundbeck Plans Boston Move as Neuroscience Ambitions Grow

Lundbeck Plans Boston Move as Neuroscience Ambitions Grow

Editorial Team25 September 2026 · 3 min

Carvykti Adds Five-Year Evidence From Earlier-Line Myeloma Study

Carvykti Adds Five-Year Evidence From Earlier-Line Myeloma Study

Editorial Team25 September 2026 · 3 min

Welireg Combination Expands Merck's Kidney Cancer Reach

Welireg Combination Expands Merck's Kidney Cancer Reach

Editorial Team25 September 2026 · 3 min

Indivior Returns Addex Programmes Ahead of Planned Merger

Indivior Returns Addex Programmes Ahead of Planned Merger

Editorial Team25 September 2026 · 3 min

ADARx Upsizes Its IPO to $446 Million Ahead of Trading

ADARx Upsizes Its IPO to $446 Million Ahead of Trading

Editorial Team25 September 2026 · 3 min

Genentech Adds Earendil to Its Bispecific Cancer Strategy

Genentech Adds Earendil to Its Bispecific Cancer Strategy

Editorial Team25 September 2026 · 3 min

Novo's Nanexa Pact Targets Longer Gaps Between Injections

Novo's Nanexa Pact Targets Longer Gaps Between Injections

Editorial Team25 September 2026 · 3 min

Basecamp Secures $140 Million as Tech Investors Back Drug Discovery

Basecamp Secures $140 Million as Tech Investors Back Drug Discovery

Editorial Team24 September 2026 · 3 min

Roche Pays $70 Million to Expand Cardiometabolic Discovery

Roche Pays $70 Million to Expand Cardiometabolic Discovery

Editorial Team24 September 2026 · 3 min

Kyverna Adds One-Year Evidence to Its Autoimmune CAR-T Case

Kyverna Adds One-Year Evidence to Its Autoimmune CAR-T Case

Editorial Team24 September 2026 · 3 min

Merck's Eye Drug Meets Efficacy Goal but Raises Safety Questions

Merck's Eye Drug Meets Efficacy Goal but Raises Safety Questions

Editorial Team24 September 2026 · 3 min

Acadia Keeps Alzheimer's Psychosis Programme Alive After Endpoint Miss

Acadia Keeps Alzheimer's Psychosis Programme Alive After Endpoint Miss

Editorial Team24 September 2026 · 3 min

Lilly's Weekly Insulin Wins US Approval

Lilly's Weekly Insulin Wins US Approval

Editorial Team24 September 2026 · 3 min

Immunovant Drops Cutaneous Lupus After a Mid-Stage Miss

Immunovant Drops Cutaneous Lupus After a Mid-Stage Miss

Editorial Team23 September 2026 · 3 min

Enveda Raises $311 Million to Take AI-Discovered Drugs Further

Enveda Raises $311 Million to Take AI-Discovered Drugs Further

Editorial Team23 September 2026 · 3 min

Novo's New York Listing Comments Stop Short of a Plan

Novo's New York Listing Comments Stop Short of a Plan

Editorial Team23 September 2026 · 3 min

Roche's Sefaxersen Hits an Interim Kidney-Disease Endpoint

Roche's Sefaxersen Hits an Interim Kidney-Disease Endpoint

Editorial Team23 September 2026 · 3 min

Roche's Enicepatide Shows a Phase 2 Diabetes Signal

Roche's Enicepatide Shows a Phase 2 Diabetes Signal

Editorial Team22 September 2026 · 3 min

Novo Targets a Tenfold Increase in Oral Wegovy Capacity

Novo Targets a Tenfold Increase in Oral Wegovy Capacity

Editorial Team22 September 2026 · 3 min

Travere Names Its Next Chief Executive

Travere Names Its Next Chief Executive

Editorial Team22 September 2026 · 3 min

Bristol Myers Plans 265 More New Jersey Job Cuts

Bristol Myers Plans 265 More New Jersey Job Cuts

Editorial Team22 September 2026 · 3 min

Lexeo's Mantle Agreement Adds an Oral Route to Its Rare-Disease Strategy

Lexeo's Mantle Agreement Adds an Oral Route to Its Rare-Disease Strategy

Editorial Team22 September 2026 · 3 min

Otsuka's FUS-ALS Result Supports a Targeted Regulatory Push

Otsuka's FUS-ALS Result Supports a Targeted Regulatory Push

Editorial Team22 September 2026 · 3 min

Vertex Broadens the Evidence for Its APOL1 Kidney Programme

Vertex Broadens the Evidence for Its APOL1 Kidney Programme

Editorial Team22 September 2026 · 3 min

Amgen Reports a Pivotal Sjögren's Win for Dazodalibep

Amgen Reports a Pivotal Sjögren's Win for Dazodalibep

Editorial Team22 September 2026 · 3 min

Celldex Clears Two Phase 3 Hurdles in Chronic Hives

Celldex Clears Two Phase 3 Hurdles in Chronic Hives

Editorial Team22 September 2026 · 3 min

Iambic's IPO Filing Gives Public Investors an AI Drug-Discovery Test

Iambic's IPO Filing Gives Public Investors an AI Drug-Discovery Test

Editorial Team22 September 2026 · 3 min

Caplyta Secures a Phase 3 Win in Bipolar Mania

Caplyta Secures a Phase 3 Win in Bipolar Mania

Editorial Team21 September 2026 · 3 min

Telix's ITM Deal Makes Manufacturing Central to Radiopharma M&A

Telix's ITM Deal Makes Manufacturing Central to Radiopharma M&A

Editorial Team21 September 2026 · 3 min

Novo Adds Early Obesity Options Through Kallyope

Novo Adds Early Obesity Options Through Kallyope

Editorial Team21 September 2026 · 3 min

Cue's Hives Result Advances the Programme, Not a Superiority Claim

Cue's Hives Result Advances the Programme, Not a Superiority Claim

Editorial Team21 September 2026 · 3 min

ADARx Puts a $1.74 Billion Valuation to the Market

ADARx Puts a $1.74 Billion Valuation to the Market

Editorial Team21 September 2026 · 3 min

TRex and Retension Test the Appetite for Biotech IPOs

TRex and Retension Test the Appetite for Biotech IPOs

Editorial Team20 September 2026 · 3 min

Electra's $350 Million IPO Tests Appetite for Cardiovascular Biotechs in a Selective Market

Electra's $350 Million IPO Tests Appetite for Cardiovascular Biotechs in a Selective Market

Editorial Team18 September 2026 · 4 min

Bristol Myers Squibb Drops ORM-6151 Phase I After Disappointing Early Data

Bristol Myers Squibb Drops ORM-6151 Phase I After Disappointing Early Data

Editorial Team18 September 2026 · 4 min

Bayer's Kerendia Approval in Type 1 Diabetes Kidney Disease Opens a New Market

Bayer's Kerendia Approval in Type 1 Diabetes Kidney Disease Opens a New Market

Editorial Team17 September 2026 · 4 min

Longeveron's ELPIS II Failure Removes Its Lead Candidate From Contention

Longeveron's ELPIS II Failure Removes Its Lead Candidate From Contention

Editorial Team17 September 2026 · 4 min

Lisata and Marea's $225 Million Merger Creates a Focused Cardiovascular Biotech

Lisata and Marea's $225 Million Merger Creates a Focused Cardiovascular Biotech

Editorial Team17 September 2026 · 4 min

Roche's $1 Billion Dualitas Deal Reinforces Its Commitment to Engineered Antibody Formats

Roche's $1 Billion Dualitas Deal Reinforces Its Commitment to Engineered Antibody Formats

Editorial Team17 September 2026 · 4 min

Novartis Bets $125 Million on Sironax's Brain Drug Delivery Platform

Novartis Bets $125 Million on Sironax's Brain Drug Delivery Platform

Editorial Team17 September 2026 · 4 min

Novo's $1.4 Billion Orbis Deal Bets on Macrocycles as the Next GLP-1 Frontier

Novo's $1.4 Billion Orbis Deal Bets on Macrocycles as the Next GLP-1 Frontier

Editorial Team17 September 2026 · 4 min

Sionna's 46% Workforce Reduction Signals a Pivot After Clinical Setbacks

Sionna's 46% Workforce Reduction Signals a Pivot After Clinical Setbacks

Editorial Team16 September 2026 · 4 min

Sling's $123 Million Series C Backs a Focused Bet on Thyroid Eye Disease

Sling's $123 Million Series C Backs a Focused Bet on Thyroid Eye Disease

Editorial Team16 September 2026 · 4 min

Novartis Ends Lifonebart ALS Programme After Phase II Futility Analysis

Novartis Ends Lifonebart ALS Programme After Phase II Futility Analysis

Editorial Team16 September 2026 · 4 min

Lilly's New-Patient Claim Changes the Oral Obesity Discussion

Lilly's New-Patient Claim Changes the Oral Obesity Discussion

Editorial Team15 September 2026 · 4 min

Bayer's Roundup Hearing Leaves the Price of Certainty Unsettled

Bayer's Roundup Hearing Leaves the Price of Certainty Unsettled

Editorial Team15 September 2026 · 4 min

Contineum's Depression Miss Tests the Value of Its Partnered Programme

Contineum's Depression Miss Tests the Value of Its Partnered Programme

Editorial Team15 September 2026 · 4 min

J&J's Reported Apollo Talks Put a Value on Corporate Focus

J&J's Reported Apollo Talks Put a Value on Corporate Focus

Editorial Team14 September 2026 · 4 min

GE HealthCare's Reported Sofie Talks Put Imaging Agents in Focus

GE HealthCare's Reported Sofie Talks Put Imaging Agents in Focus

Editorial Team14 September 2026 · 4 min

Scholar Rock's First Approval Opens a New Layer of SMA Treatment

Scholar Rock's First Approval Opens a New Layer of SMA Treatment

Editorial Team14 September 2026 · 4 min

Roche's MediLink Programme Adds Another Serious Lung Cancer Contender

Roche's MediLink Programme Adds Another Serious Lung Cancer Contender

Editorial Team14 September 2026 · 4 min

Definium's Anxiety Result Brings an FDA Filing Closer

Definium's Anxiety Result Brings an FDA Filing Closer

Editorial Team14 September 2026 · 4 min

Electra's IPO Plans Put a Price on Reaching the Next Clinical Milestone

Electra's IPO Plans Put a Price on Reaching the Next Clinical Milestone

Editorial Team14 September 2026 · 4 min

Corbus Puts a Non-GLP-1 Obesity Pill Back Into Contention

Corbus Puts a Non-GLP-1 Obesity Pill Back Into Contention

Editorial Team14 September 2026 · 4 min

Lilly Ends an Early Obesity Programme as the Development Bar Rises

Lilly Ends an Early Obesity Programme as the Development Bar Rises

Editorial Team14 September 2026 · 4 min

BioNTech's Gotistobart Update Strengthens the Case Ahead of Pivotal Results

BioNTech's Gotistobart Update Strengthens the Case Ahead of Pivotal Results

Editorial Team14 September 2026 · 4 min

Cullinan and Taiho Gain Six Months of Progression-Free Survival

Cullinan and Taiho Gain Six Months of Progression-Free Survival

Editorial Team14 September 2026 · 4 min

GSK's Jideytro Makes Its Case for Earlier Use

GSK's Jideytro Makes Its Case for Earlier Use

Editorial Team14 September 2026 · 4 min

Ivonescimab Adds Overall-Survival Evidence to Its Keytruda Challenge

Ivonescimab Adds Overall-Survival Evidence to Its Keytruda Challenge

Editorial Team14 September 2026 · 4 min

GSK's Ris-Rez Results Raise the Stakes in Small-Cell Lung Cancer

GSK's Ris-Rez Results Raise the Stakes in Small-Cell Lung Cancer

Editorial Team13 September 2026 · 4 min

AstraZeneca's Etcamah Miss Narrows the Breast Cancer Expansion Case

AstraZeneca's Etcamah Miss Narrows the Breast Cancer Expansion Case

Editorial Team13 September 2026 · 4 min

Handa's Cabozantinib Approval Opens a Commercial Test for Reformulation

Handa's Cabozantinib Approval Opens a Commercial Test for Reformulation

Editorial Team12 September 2026 · 4 min

Novo and Lilly's Oral Obesity Race Moves Into the Prescription Data

Novo and Lilly's Oral Obesity Race Moves Into the Prescription Data

Editorial Team12 September 2026 · 4 min

Exelixis Faces a Three-Month Shift in Its Next Launch Opportunity

Exelixis Faces a Three-Month Shift in Its Next Launch Opportunity

Editorial Team11 September 2026 · 4 min

Disc Medicine's Blood Disorder Data Put Convenience Under the Microscope

Disc Medicine's Blood Disorder Data Put Convenience Under the Microscope

Editorial Team11 September 2026 · 4 min

Tyra Shows the Cost of Elevated Expectations

Tyra Shows the Cost of Elevated Expectations

Editorial Team11 September 2026 · 4 min

Takeda's Research Handover Puts Continuity on Trial

Takeda's Research Handover Puts Continuity on Trial

Editorial Team10 September 2026 · 4 min

Novartis Must Rebuild the Avidity Case

Novartis Must Rebuild the Avidity Case

Editorial Team9 September 2026 · 5 min

Structure Raises the Bar in Oral Obesity

Structure Raises the Bar in Oral Obesity

Editorial Team8 September 2026 · 4 min

Pfizer's Seagen Deal Enters Its Harder Phase

Pfizer's Seagen Deal Enters Its Harder Phase

Editorial Team5 September 2026 · 4 min